Good MorningSeptember got off to a great start with the major indices moving up to set new all-time highs. The tech-heavy NASDAQ Composite led the charge with a gain near 1.40% with the S&P 500 and Dow Jones Industrial close behind. Apple, despite newly split shares, led the tech-sector with a gain of 4.0% with Dow component Walmart up more than 6.0%.
Tuesday’s move was supported by better than expected manufacturing data. The ISM Manufacturing index came in at a hotter-than-expected 56 with notable strength in hiring and new orders. The data is only the latest indication of accelerating economic activity in the U.S. Traders are eyeing the much-anticipated Non-farm-payrolls figure due out on Friday. The consensus is jobs rose more than 1.1 million in August.
Featured: Two Amazing Traders Discuss "Fix" For Current Markets (Rob Booker) 
|
Markets | | |
Data analytics firm Alteryx (NYSE: AYX) stock took a shocking collapse on its Q2 2020 earnings release shaving more than (-35%) off its share price in the following two-days. Their analytics processing automation (APA) platform experienced churn in organizations with under $100 million in annual s... Read the Full Story |
|
From Our PartnersFormer Lehman Brothers executive reveals one of Wall Street's best kept secrets.
A proven system for turning $500 into $650,000 (or more) - without touching the stock market.
In fact, this system is responsible for the most profitable investment of all time! | | Click here for details>> |
|
Markets | | | The S&P 500 (NYSEARCA: SPY) has hit two of three upside targets outlined a few weeks ago in MarketBeat original article “S&P 500 in ‘Fake it Til You Make It’ Melt-up Trajectories”. The market has shunned off any skepticism as optimism for a COVID-19 vaccine and dovish... Read the Full Story |
|
Markets | | |
Some stocks have done shockingly well in the midst of a pandemic, and that really shouldn't be a surprise. We've seen explosive growth come out of it since the depths of April's disaster, and Sorrento Therapeutics (NASDAQ: SRNE) has recently emerged as one of the biggest gainers in the field. It m... Read the Full Story |
|
|
Markets | | | Big Lots Suffers From High-Expectation Syndrome
Looking at Big Lots (NYSE:BIG) second-quarter report I can find absolutely no reason why the stock tanked 10% after its release. Looking into the company’s expectations and taking note of an incredibly high short-interest (above 20% even today) ... Read the Full Story |
|
Markets | | |
It's easy to brush aside a small firm as a bad investment. It's even easier when it's a small pharmaceutical firm. But what would you say to a small pharmaceutical that's increased its value five-fold in the space of as many years? That's the proposition you get with Corbus Pharmaceuticals (NASDAQ... Read the Full Story |
|
From Our PartnersThis real-life Wall Street insider just revealed the TWO forces driving stock prices today. Get ready to "unlearn" all you thought you knew about the markets. | | Details here |
|
The Early Bird Stock Of The Day Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland. | | View Today's Stock Pick |
|
